Albemarle Corporation filed its quarterly report on Form 10-Q with the SEC on November 4, 2026, covering the three and nine months ended September 30, 2026, disclosing a return to profitability in the third quarter alongside significant year-over-year revenue growth.

Key Highlights

  • Third-quarter net sales of $1,553,097 thousand compared to $1,307,829 thousand in the same period of 2025, according to the filing.
  • Net income attributable to Albemarle Corporation of $296,755 thousand for the three months ended September 30, 2026, versus a net loss of $160,694 thousand in Q3 2025.
  • Diluted earnings per share of $2.15 for the third quarter, compared to a diluted loss per share of $1.72 in the prior-year period.
  • Nine-month net sales reached $4,725,141 thousand, up from $3,714,702 thousand for the same period in 2025.
  • Cash and cash equivalents of $1,845,999 thousand as of September 30, 2026, versus $1,618,001 thousand at December 31, 2025.
  • Long-term debt decreased to $1,806,750 thousand at September 30, 2026, from $3,119,464 thousand at December 31, 2025.
  • 118,009,849 shares of common stock outstanding as of October 28, 2026, as stated on the filing's cover page.

Albemarle Reports Q3 2026 Financial Results and Balance Sheet Position

Albemarle Corporation (NYSE:ALB), a specialty chemicals company, reported third-quarter 2026 net sales of $1,553,097 thousand, a year-over-year increase from $1,307,829 thousand, according to the unaudited consolidated statements of income included in the filing. Gross profit for the quarter was $300,724 thousand, compared to $117,610 thousand in Q3 2025. Operating profit came in at $148,160 thousand, contrasting with an operating loss of $216,986 thousand in the prior-year quarter, which the filing noted included goodwill impairment charges of $181,070 thousand.

For the nine months ended September 30, 2026, the company reported net income attributable to Albemarle Corporation of $1,095,805 thousand, compared to a net loss of $96,449 thousand for the same period in 2025. The filing also disclosed a loss on sale of business of $95,018 thousand recognized in the nine-month period, with no comparable amount in the prior year. Equity in net income of unconsolidated investments was $205,350 thousand for the third quarter and $453,207 thousand for the nine-month period, reflecting the company's stakes in joint ventures and affiliates. Purchases from related unconsolidated affiliates totaled $458.5 million for the three months ended September 30, 2026.

On the balance sheet, total assets were reported at $16,083,315 thousand as of September 30, 2026. Total equity increased to $10,820,029 thousand from $9,781,461 thousand at December 31, 2025. The filing shows that assets and liabilities previously classified as held for sale, which totaled $863,475 thousand and $251,723 thousand respectively at December 31, 2025, carried zero balances by September 30, 2026, indicating the completion of the related transaction during the period. Mandatory convertible preferred stock, Series A, remained at 2,300 thousand shares issued and outstanding in both periods.

What Was Disclosed

Albemarle's Form 10-Q for the quarter ended September 30, 2026, filed November 4, 2026, presented unaudited financial statements showing a return to quarterly profitability, higher net sales year-over-year, reduced long-term debt, and the completion of a previously announced business sale.